中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 4
Apr.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(4): 778-783

Mechanism of action of tumor necrosis factor superfamily member 14 in chronic liver diseases

DOI: 10.12449/JCH250427
  • 1.

    Department of Business，Institute of Medical Device Testing Technology，Shanxi Provincial Inspection and Testing Center/Shanxi Institute of Standard Measurement Technology，Taiyuan 030000，China

  • 2.

    Cancer Center，Shanxi Bethune Hospital，Shanxi Academy of Medical Sciences，Tongji Shanxi Hospital，The Third Hospital of Shanxi Medical University，Taiyuan 030000，China

Research funding:

Shanxi Natural Science Foundation (202303021222308);

Shanxi Bethune Hospital Talent Introduction Research Start-Up Fund (2023RC56)

More Information
  • Corresponding author: MA Yanan， myn15834066882@126.com （ORCID： 0009-0007-9277-7202）
  • Received Date: 2024-08-30
  • Accepted Date: 2024-11-08
  • Published Date: 2025-04-25
    Abstract
  • Tumor necrosis factor superfamily member 14 （TNFSF14） is a new member of the tumor necrosis factor superfamily member， and it mediates diverse biological functions through binding with herpes virus entry mediator， lymphotoxin-β receptor， and soluble decoy receptor 3， thereby exerting an important regulatory effect in inflammatory diseases， fibrotic diseases， and anti-tumor immunity. In recent years， the mechanism of LIGHT in the development and progression of liver diseases and its role in treatment have attracted more and more attention.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    YOUNOSSI ZM, WONG G, ANSTEE QM, et al. The global burden of liver disease[J]. Clin Gastroenterol Hepatol, 2023, 21( 8): 1978- 1991. DOI: 10.1016/j.cgh.2023.04.015.
    [2]
    SHUPTRINE CW, PEREZ VM, SELITSKY SR, et al. Shining a LIGHT on myeloid cell targeted immunotherapy[J]. Eur J Cancer, 2023, 187: 147- 160. DOI: 10.1016/j.ejca.2023.03.040.
    [3]
    MAURI DN, EBNER R, MONTGOMERY RI, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator[J]. Immunity, 1998, 8( 1): 21- 30. DOI: 10.1016/s1074-7613(00)80455-0.
    [4]
    CROFT M, SIEGEL RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases[J]. Nat Rev Rheumatol, 2017, 13( 4): 217- 233. DOI: 10.1038/nrrheum.2017.22.
    [5]
    WARE CF. Targeting the LIGHT-HVEM pathway[J]. Adv Exp Med Biol, 2009, 647: 146- 155. DOI: 10.1007/978-0-387-89520-8_10.
    [6]
    PIAO WJ, KASINATH V, SAXENA V, et al. LTβR signaling controls lymphatic migration of immune cells[J]. Cells, 2021, 10( 4): 747. DOI: 10.3390/cells10040747.
    [7]
    ZOU GM, HU WY. LIGHT regulates CD86 expression on dendritic cells through NF-kappaB, but not JNK/AP-1 signal transduction pathway[J]. J Cell Physiol, 2005, 205( 3): 437- 443. DOI: 10.1002/jcp.20420.
    [8]
    LIANG CJ, XU YC, LI GM, et al. Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis[J]. Onco Targets Ther, 2017, 10: 417- 428. DOI: 10.2147/OTT.S127202.
    [9]
    ŠEDÝ JR, RAMEZANI-RAD P. HVEM network signaling in cancer[J]. Adv Cancer Res, 2019, 142: 145- 186. DOI: 10.1016/bs.acr.2019.01.004.
    [10]
    FROMM G, de SILVA S, SCHREIBER TH. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists[J]. Front Immunol, 2023, 14: 1236332. DOI: 10.3389/fimmu.2023.1236332.
    [11]
    STEINBERG MW, CHEUNG TC, WARE CF. The signaling networks of the herpesvirus entry mediator(TNFRSF14) in immune regulation[J]. Immunol Rev, 2011, 244( 1): 169- 187. DOI: 10.1111/j.1600-065X.2011.01064.x.
    [12]
    BORGHI A, VERSTREPEN L, BEYAERT R. TRAF2 multitasking in TNF receptor-induced signaling to NF-κB, MAP kinases and cell death[J]. Biochem Pharmacol, 2016, 116: 1- 10. DOI: 10.1016/j.bcp.2016.03.009.
    [13]
    CELIK S, SHANKAR V, RICHTER A, et al. Proinflammatory and prothrombotic effects on human vascular endothelial cells of immune-cell-derived LIGHT[J]. Eur J Med Res, 2009, 14( 4): 147- 156. DOI: 10.1186/2047-783x-14-4-147.
    [14]
    HAYBAECK J, ZELLER N, WOLF MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma[J]. Cancer Cell, 2009, 16( 4): 295- 308. DOI: 10.1016/j.ccr.2009.08.021.
    [15]
    LI GQ, SHANG YH, CAO ZH, et al. Role of TNFSF14 and its receptors LTβR and HVEM in pathogenesis of virus hepatitis[J]. Chin J Immunol, 2015, 31( 12): 1591- 1594. DOI: 10.3969/j.issn.1000-484X.2015.12.002.

    李桂清, 尚宇航, 曹朝晖, 等. TNFSF14及其受体LTβR和HVEM在病毒肝炎中的作用[J]. 中国免疫学杂志, 2015, 31( 12): 1591- 1594. DOI: 10.3969/j.issn.1000-484X.2015.12.002.
    [16]
    WASHBURN ML, KOVALEV GI, KOROLEVA E, et al. LIGHT induces distinct signals to clear an AAV-expressed persistent antigen in the mouse liver and to induce liver inflammation[J]. PLoS One, 2010, 5( 5): e10585. DOI: 10.1371/journal.pone.0010585.
    [17]
    LAI DM, LV ZJ, LU XH, et al. LIGHT amplification by NF-κB contributes to TLR3 signaling pathway-induced acute hepatitis[J]. Mediators Inflamm, 2023, 2023: 3732315. DOI: 10.1155/2023/3732315.
    [18]
    ZHANG YL, JIANG WZ, FAN Y, et al. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant[J]. J Virol Methods, 2008, 153( 2): 142- 148. DOI: 10.1016/j.jviromet.2008.07.013.
    [19]
    JIANG WZ, CHEN R, KONG XB, et al. Immunization with adenovirus LIGHT-engineered dendritic cells induces potent T cell responses and therapeutic immunity in HBV transgenic mice[J]. Vaccine, 2014, 32( 35): 4565- 4570. DOI: 10.1016/j.vaccine.2014.06.039.
    [20]
    MA SY, CHEN XH, TAN QH, et al. An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells[J]. Cell Cycle, 2018, 17( 10): 1220- 1234. DOI: 10.1080/15384101.2018.1471312.
    [21]
    OTTERDAL K, HAUKELAND JW, YNDESTAD A, et al. Increased serum levels of LIGHT/TNFSF14 in nonalcoholic fatty liver disease: Possible role in hepatic inflammation[J]. Clin Transl Gastroenterol, 2015, 6( 7): e95. DOI: 10.1038/ctg.2015.23.
    [22]
    HERRERO-CERVERA A, VINUÉ Á, BURKS DJ, et al. Genetic inactivation of the LIGHT(TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis[J]. Diabetologia, 2019, 62( 11): 2143- 2157. DOI: 10.1007/s00125-019-4962-6.
    [23]
    MIAO XL, GUO Y, ZENG S, et al. HES5-mediated repression of LIGHT transcription may contribute to apoptosis in hepatocytes[J]. Cell Death Discov, 2021, 7( 1): 308. DOI: 10.1038/s41420-021-00707-6.
    [24]
    SAUNDERS BM, RUDNICKA C, FILIPOVSKA A, et al. Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL-6 production[J]. Immunol Cell Biol, 2018, 96( 1): 41- 53. DOI: 10.1111/imcb.1002.
    [25]
    AGOSTINO M, ROONEY J, HERAT L, et al. TNFSF14-derived molecules as a novel treatment for obesity and type 2 diabetes[J]. Int J Mol Sci, 2021, 22( 19): 10647. DOI: 10.3390/ijms221910647.
    [26]
    XU Y, PENG WP, HAN D, et al. Maiwei Yangfei decoction prevents bleomycin-induced pulmonary fibrosis in mice[J]. Exp Ther Med, 2021, 22( 5): 1306. DOI: 10.3892/etm.2021.10741.
    [27]
    SCHIMMEL K, ICHIMURA K, REDDY S, et al. Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target[J]. Front Cardiovasc Med, 2022, 9: 886553. DOI: 10.3389/fcvm.2022.886553.
    [28]
    MANRESA MC, CHIANG AWT, KURTEN RC, et al. Increased production of LIGHT by T cells in eosinophilic esophagitis promotes differentiation of esophageal fibroblasts toward an inflammatory phenotype[J]. Gastroenterology, 2020, 159( 5): 1778- 1792. e 13. DOI: 10.1053/j.gastro.2020.07.035.
    [29]
    STEELE H, CHENG J, WILLICUT A, et al. TNF superfamily control of tissue remodeling and fibrosis[J]. Front Immunol, 2023, 14: 1219907. DOI: 10.3389/fimmu.2023.1219907.
    [30]
    KANAI S, FUJIWARA H, MIZUNO S, et al. Increased expression of TNFRSF14 and LIGHT in biliary epithelial cells of patients with primary sclerosing cholangitis[J]. Dig Liver Dis, 2024, 56( 2): 305- 311. DOI: 10.1016/j.dld.2023.08.057.
    [31]
    ELßNER C, GOEPPERT B, LONGERICH T, et al. Nuclear translocation of RELB is increased in diseased human liver and promotes ductular reaction and biliary fibrosis in mice[J]. Gastroenterology, 2019, 156( 4): 1190- 1205. e 14. DOI: 10.1053/j.gastro.2018.11.018.
    [32]
    YUAN ZH, WANG J, ZHANG HR, et al. Triptolide increases resistance to bile duct ligation-induced liver injury and fibrosis in mice by inhibiting RELB[J]. Front Nutr, 2022, 9: 1032722. DOI: 10.3389/fnut.2022.1032722.
    [33]
    LIANG QS, XIE JG, YU CP, et al. Splenectomy improves liver fibrosis via tumor necrosis factor superfamily 14(LIGHT) through the JNK/TGF-β1 signaling pathway[J]. Exp Mol Med, 2021, 53( 3): 393- 406. DOI: 10.1038/s12276-021-00574-2.
    [34]
    SKEATE JG, OTSMAA ME, PRINS R, et al. TNFSF14: Lighting the way for effective cancer immunotherapy[J]. Front Immunol, 2020, 11: 922. DOI: 10.3389/fimmu.2020.00922.
    [35]
    HAN B, WU LQ, MA X, et al. Synergistic effect of IFN-γ gene on LIGHT-induced apoptosis in HepG2 cells via down regulation of Bcl-2[J]. Artif Cells Blood Substit Immobil Biotechnol, 2011, 39( 4): 228- 238. DOI: 10.3109/10731199.2010.538403.
    [36]
    LI J, SHEN F, WU D, et al. Expression level of Bcl-XL critically affects sensitivity of hepatocellular carcinoma cells to LIGHT-enhanced and interferon-gamma-induced apoptosis[J]. Oncol Rep, 2007, 17( 5): 1067- 1075.
    [37]
    CHEN MC, HSU TL, LUH TY, et al. Overexpression of bcl-2 enhances LIGHT- and interferon-gamma-mediated apoptosis in Hep3BT2 cells[J]. J Biol Chem, 2000, 275( 49): 38794- 38801. DOI: 10.1074/jbc.M003292200.
    [38]
    MAKER AV, ITO H, MO QX, et al. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases[J]. Cancer Immunol Res, 2015, 3( 4): 380- 388. DOI: 10.1158/2326-6066.CIR-14-0212.
    [39]
    QIAO GL, QIN JZ, KUNDA N, et al. LIGHT elevation enhances immune eradication of colon cancer metastases[J]. Cancer Res, 2017, 77( 8): 1880- 1891. DOI: 10.1158/0008-5472.CAN-16-1655.
    [40]
    CHENG JM, LI YY, WANG XH, et al. Response stratification in the first-line combined immunotherapy of hepatocellular carcinoma at genomic, transcriptional and immune repertoire levels[J]. J Hepatocell Carcinoma, 2021, 8: 1281- 1295. DOI: 10.2147/JHC.S326356.
    [41]
    QIU YY, ZHANG J, ZENG FY, et al. Roles of the peroxisome proliferator-activated receptors(PPARs) in the pathogenesis of nonalcoholic fatty liver disease(NAFLD)[J]. Pharmacol Res, 2023, 192: 106786. DOI: 10.1016/j.phrs.2023.106786.
    [42]
    AMELIMOJARAD M, AMELIMOJARAD M, CUI XN. Weighted gene co-expression network analysis identified GBP2 connected to PPARα activity and liver cancer[J]. Sci Rep, 2024, 14( 1): 20745. DOI: 10.1038/s41598-024-70832-6.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (449) PDF downloads(40) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return